Suven Secures Product Patents in New Zealand, USA | CORPORATE ETHOS

Suven Secures Product Patents in New Zealand, USA

By: | May 29, 2018
suven life sciences

May 29: Hyderabad-based biopharma firm  Suven Life Sciences Ltd on Tuesday announced that the company has been granted one product patent from New Zealand (728915) and another one product patent from USA (9951045) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034.

According to the company, the granted claims of the patents include the class of selective H3 and 5-HT4 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.

Suven shares were trading in red at Rs 192.50, down 2.18% from the previous closing of Rs 196.80, on BSE at 12.52 pm today.